|
|
| | TAK-063 Basic information |
| Product Name: | TAK-063 | | Synonyms: | TAK-063;1-[2-Fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one;Balipodect;TAK 063;TAK063; Pyridone 6[1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one];CS-1534;TAK-063(Balipodect);TAK063, TAK 063, TAK-063, BALIPODECT | | CAS: | 1238697-26-1 | | MF: | C23H17FN6O2 | | MW: | 428.42 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 1238697-26-1.mol |  |
| | TAK-063 Chemical Properties |
| Boiling point | 612.3±65.0 °C(Predicted) | | density | 1.37±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:55.0(Max Conc. mg/mL);128.38(Max Conc. mM) | | form | A crystalline solid | | pka | -0.34±0.12(Predicted) |
| | TAK-063 Usage And Synthesis |
| Description | TAK-063 is a potent inhibitor of phosphodiesterase 10A (PDE10A; IC50 = 0.3 nM). It is >15,000-fold selective for PDE10A over other PDEs and exhibits <50% inhibition at 91 receptors, ion channels, and enzymes at a concentration of 10 μM. TAK-063 (0.3 mg/kg) increases cAMP and cGMP levels by 1.3- and 2.14-fold, respectively, in the striatum of mice. It reverses hyperlocomotion induced by PCP (Item Nos. 14276 | ISO60194) with a minimum effective dose (MED) of 0.3 mg/kg, p.o., in wild-type mice but has no effect in PDE10A knockout mice at doses up to 1 mg/kg. TAK-063 also reverses hyperlocomotion induced by (+)-MK-801 (MED = 0.1 mg/kg, p.o.) but has no effect on plasma prolactin or glucose levels in rats. |
| | TAK-063 Preparation Products And Raw materials |
|